Global Market Direct’s pharmaceuticals report, “CuraVac, Inc. - Product Pipeline Review - 2013” provides data on the CuraVac, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, CuraVac, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from CuraVac, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- CuraVac, Inc. - Brief CuraVac, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of CuraVac, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of CuraVac, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the CuraVac, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate CuraVac, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of CuraVac, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the CuraVac, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with CuraVac, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of CuraVac, Inc. and identify potential opportunities in those areas.
Table Of Contents
CuraVac, Inc. - Product Pipeline Review - 2013 Table of Contents 2 List of Tables 3 List of Figures 3 CuraVac, Inc. Snapshot 4 CuraVac, Inc. Overview 4 Key Information 4 Key Facts 4 CuraVac, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 CuraVac, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 CuraVac, Inc. - Pipeline Products Glance 9 CuraVac, Inc. - Early Stage Pipeline Products 9 Pre-Clinical Products/Combination Treatment Modalities 9 CuraVac, Inc. - Drug Profiles 10 Vaccine For Myasthenia Gravis 10 Product Description 10 Mechanism of Action 10 RandD Progress 10 CuraVac, Inc. - Pipeline Analysis 11 CuraVac, Inc. - Pipeline Products by Therapeutic Class 11 CuraVac, Inc. - Pipeline Products by Route of Administration 12 CuraVac, Inc. - Locations And Subsidiaries 13 Head Office 13 Appendix 14 Methodology 14 Coverage 14 Secondary Research 14 Primary Research 14 Expert Panel Validation 14 Contact Us 15 Disclaimer 15
List of Tables
CuraVac, Inc., Key Information 4 CuraVac, Inc., Key Facts 4 CuraVac, Inc. - Pipeline by Indication, 2013 6 CuraVac, Inc. - Pipeline by Stage of Development, 2013 7 CuraVac, Inc. - Monotherapy Products in Pipeline, 2013 8 CuraVac, Inc. - Pre-Clinical, 2013 9 CuraVac, Inc. - Pipeline By Therapeutic Class, 2013 11 CuraVac, Inc. - Pipeline By Route of Administration, 2013 12
List of Figures
CuraVac, Inc. - Pipeline by Indication, 2013 6 CuraVac, Inc. - Pipeline by Stage of Development, 2013 7 CuraVac, Inc. - Monotherapy Products in Pipeline, 2013 8 CuraVac, Inc. - Pipeline By Therapeutic Class, 2013 11 CuraVac, Inc. - Pipeline By Route of Administration, 2013 12